氟比洛芬与萘普生治疗类风湿性关节炎的多中心比较：118例患者的四周研究
A multicentre comparison of flurbiprofen and naproxen in rheumatoid arthritis: a four-week study in 118 patients.
作者信息
Cherie-Ligniere G, Colamussi V, Cozzolongo A C, Loizzi P, Frizziero L, Mattara L, Zorzin L
出版信息
J Int Med Res. 1983;11(2):85-9. doi: 10.1177/030006058301100204.
One-hundred and eighteen patients with rheumatoid arthritis were treated for 4 weeks with flurbiprofen 300 mg/day (sixty patients) or naproxen 750 mg/day (fifty-eight patients) in a six-centre randomized trial. Flurbiprofen proved to be more effective than naproxen in reducing morning stiffness (p less than 0.01), Ritchie articular index (p less than 0.01) and number of swollen joints (p less than 0.05) and in relieving night pain (p less than 0.01). The incidence and severity of side-effects, mainly gastric, were both low and similar with flurbiprofen (17%) and naproxen (19%).
在一项六中心随机试验中，118例类风湿性关节炎患者接受了为期4周的治疗，其中60例患者每日服用氟比洛芬300毫克，58例患者每日服用萘普生750毫克。结果表明，氟比洛芬在减轻晨僵（p<0.01）、里奇关节指数（p<0.01）和关节肿胀数量（p<0.05）以及缓解夜间疼痛（p<0.01）方面比萘普生更有效。副作用的发生率和严重程度主要为胃肠道反应，氟比洛芬（17%）和萘普生（19%）的发生率均较低且相似。
Zotero 插件